Ceftazidime–avibactam and ceftolozane–tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary

Acquired qnrVC1 and bla NDM-1 resistance markers in an international high-risk Pseudomonas aeruginosa ST773 clone

(2019) Bela Kocsis et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods

(2017) Frieder Schaumburg et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria

(2017) Mark D. Gonzalez et al.   Annals of Laboratory Medicine

Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

(2016) Deanna J. Buehrle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

(2016) David van Duin et al.   CLINICAL INFECTIOUS DISEASES

What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?

(2016) Ivan Gentile et al.   Expert Review of Anti-Infective Therapy

Carbapenem inactivation: a very affordable and highly specific method for phenotypic detection of carbapenemase-producing Pseudomonas aeruginosa isolates compared with other methods

(2016) Mohammad Taghi Akhi et al.   JOURNAL OF CHEMOTHERAPY

Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections

(2016) Celeste Vinluan et al.   Drug Design Development and Therapy

Comparison of Verona Integron-Borne Metallo-β-Lactamase (VIM) Variants Reveals Differences in Stability and Inhibition Profiles

(2015) Anne Makena et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Carbapenem Inactivation Method (CIM), a Simple and Low-Cost Alternative for the Carba NP Test to Assess Phenotypic Carbapenemase Activity in Gram-Negative Rods

(2015) Kim van der Zwaluw et al.   PLoS One

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries

(2014) M. Castanheira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

(2013) David E. Ehmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Multiplex PCR for detection of acquired carbapenemase genes

(2011) Laurent Poirel et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Pseudomonas Aeruginosa: Resistance to the Max

(2011) Keith Poole   Frontiers in Microbiology

Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa

(2010) B. Moya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

(2010) Karthikeyan K Kumarasamy et al.   LANCET INFECTIOUS DISEASES